SLC19A3
Thiamine transporter 2
Also known as: S19A3_HUMAN, THTR2
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q9BZV2
- Gene
- SLC19A3
- Ensembl
- ENSG00000135917
- Chromosome
- 2
- Canonical length
- 496 aa
- Protein class
- Disease related genes, Human disease related genes, Metabolic proteins, Potential drug targets, Predicted membrane proteins, Transporters
- Subcellular location
- Nucleoplasm,Plasma membrane,Cytosol
OverviewNCBI Gene
This gene encodes a ubiquitously expressed transmembrane thiamine transporter that lacks folate transport activity. Mutations in this gene cause biotin-responsive basal ganglia disease (BBGD); a recessive disorder manifested in childhood that progresses to chronic encephalopathy, dystonia, quadriparesis, and death if untreated. Patients with BBGD have bilateral necrosis in the head of the caudate nucleus and in the putamen. Administration of high doses of biotin in the early progression of the disorder eliminates pathological symptoms while delayed treatment results in residual paraparesis, mild cognitive disability, or dystonia. Administration of thiamine is ineffective in the treatment of this disorder. Experiments have failed to show that this protein can transport biotin. Mutations in this gene also cause a Wernicke's-like encephalopathy.[provided by RefSeq, Jan 2010]
Canonical amino-acid sequenceUniProt
496 residues, UniProt reviewed canonical sequence.
>Q9BZV2|SLC19A3
1 MDCYRTSLSS SWIYPTVILC LFGFFSMMRP SEPFLIPYLS GPDKNLTSAE ITNEIFPVWT
61 YSYLVLLLPV FVLTDYVRYK PVIILQGISF IITWLLLLFG QGVKTMQVVE FFYGMVTAAE
121 VAYYAYIYSV VSPEHYQRVS GYCRSVTLAA YTAGSVLAQL LVSLANMSYF YLNVISLASV
181 SVAFLFSLFL PMPKKSMFFH AKPSREIKKS SSVNPVLEET HEGEAPGCEE QKPTSEILST
241 SGKLNKGQLN SLKPSNVTVD VFVQWFQDLK ECYSSKRLFY WSLWWAFATA GFNQVLNYVQ
301 ILWDYKAPSQ DSSIYNGAVE AIATFGGAVA AFAVGYVKVN WDLLGELALV VFSVVNAGSL
361 FLMHYTANIW ACYAGYLIFK SSYMLLITIA VFQIAVNLNV ERYALVFGIN TFIALVIQTI
421 MTVIVVDQRG LNLPVSIQFL VYGSYFAVIA GIFLMRSMYI TYSTKSQKDV QSPAPSENPD
481 VSHPEEESNI IMSTKLLocalizationUniProt · AlphaFold · HPA
Whether an antibody against SLC19A3 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Cell surface
- Secreted
- No
- Transmembrane segments
- 12
- Mean surface accessibility (rSASA)
- 0.32
- Highest tissue expression
- 44 nTPM
Expression across tissuesHPA
Tissue
- adipose tissue: 44 nTPM
- placenta: 23 nTPM
- breast: 19 nTPM
- liver: 13 nTPM
- duodenum: 8.5 nTPM
- gallbladder: 5.4 nTPM
Single-cell type
- adipocytes: 672 nCPM
- syncytiotrophoblasts: 311 nCPM
- distal convoluted tubule cells: 197 nCPM
- cytotrophoblasts: 137 nCPM
- migrating cytotrophoblasts: 72 nCPM
- renal connecting tubule cells: 34 nCPM
Immune cell
- basophil: 6.9 nTPM
- neutrophil: 3.2 nTPM
- NK-cell: 2.2 nTPM
- naive B-cell: 1.2 nTPM
- eosinophil: 0.9 nTPM
- plasmacytoid DC: 0.9 nTPM
Brain region
- thalamus: 19 nTPM
- pons: 18 nTPM
- medulla oblongata: 18 nTPM
- amygdala: 17 nTPM
- spinal cord: 17 nTPM
- cerebellum: 17 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about SLC19A3.
Disease | AllUniProt
Conditions SLC19A3 is implicated in, by any mechanism.
- Basal ganglia disease, biotin-thiamine responsive (BTBGD) MIM:607483
Disease | GeneticClinVar
77 pathogenic / likely-pathogenic of 714 ClinVar records.
Conditions with pathogenic or likely-pathogenic variants.
- Biotin-responsive basal ganglia disease
- Inborn genetic diseases
- Thiamine metabolism dysfunction syndrome 2 (biotin/thiamine-responsive basal ganglia disease type)
- SLC19A3-related disorder
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.59
- gnomAD pLI
- 0.1
- gnomAD missense Z
- -0.37
- DepMap mean gene effect
- -0.11
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- pyridoxine transport
- thiamine diphosphate biosynthetic process
- thiamine transmembrane transport
- thiamine transport
- thiamine-containing compound metabolic process
Molecular functions
Cellular components
Protein domainsUniProt · Pfam · InterPro
- Reduced folate carrier
- MFS transporter superfamily
- Reduced folate carrier
- Thiamine transporter 2
KeywordsUniProt
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads SLC19A3 as an antibody target. Whether an autoantibody or antibody against SLC19A3 could matter depends on whether native SLC19A3 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
SLC19A3 is annotated at the cell surface, where native SLC19A3 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.
Annotation status
The present source text does not explicitly label SLC19A3 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...